Blog

Currently, over 100 biosimilars are used in clinical practice and the total clinical experience with biosimilar medicines exceeds two billion treatment days. There are about forty biosimilar of nine originator mAbs authorized in the EU and US and there is no evidence of differences in safety, immunogenicity, and efficacy between biosimilar and originator products. One of the main […]

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Baltimore, MD. Link to watch the presentation is below:

Testing

A Q&A with Rick Layer, Vice President, Myrtelle’s Head of Pharmacology and Translational Science New research is changing the way we think about oligodendrocytes. Below we breakdown some common questions: How are oligodendrocytes involved in brain functions like learning and memory? We’ve known for a long time that cells called “neurons” pass information along processes